Your browser doesn't support javascript.
loading
Use of high flow nasal cannula in patients with acute respiratory failure in general wards under intensivists supervision: a single center observational study.
Colombo, Sebastiano Maria; Scaravilli, Vittorio; Cortegiani, Andrea; Corcione, Nadia; Guzzardella, Amedeo; Baldini, Luca; Cassinotti, Elisa; Canetta, Ciro; Carugo, Stefano; Hu, Cinzia; Fracanzani, Anna Ludovica; Furlan, Ludovico; Paleari, Maria Chiara; Galazzi, Alessandro; Tagliabue, Paola; Peyvandi, Flora; Blasi, Francesco; Grasselli, Giacomo.
Afiliação
  • Colombo SM; Department of Anaesthesia and Intensive Care Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Sforza, 35, 20122, Milan, Lombardia, Italy.
  • Scaravilli V; Department of Pathophysiology and Transplantation, University of Milan, Milan, Lombardia, Italy.
  • Cortegiani A; Department of Anaesthesia and Intensive Care Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Sforza, 35, 20122, Milan, Lombardia, Italy.
  • Corcione N; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Lombardia, Italy.
  • Guzzardella A; Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Sicilia, Italy.
  • Baldini L; Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Sicilia, Italy.
  • Cassinotti E; Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Canetta C; Azienda Ospedaliera Antonio Caldarelli, Interventional Pulmunology, Naples, Campania, Italy.
  • Carugo S; Department of Pathophysiology and Transplantation, University of Milan, Milan, Lombardia, Italy.
  • Hu C; Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Fracanzani AL; Department of Oncology and Hemato-oncology, University of Milan, Milan, Lombardia, Italy.
  • Furlan L; Department of Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Paleari MC; Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Galazzi A; Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Tagliabue P; Department of Clinical Sciences and Community Health, University of Milan, Milan, Lombardia, Italy.
  • Peyvandi F; Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
  • Blasi F; Department of Pathophysiology and Transplantation, University of Milan, Milan, Lombardia, Italy.
  • Grasselli G; Unit of Internal Medicine and Metabolic Disease, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy.
Respir Res ; 23(1): 171, 2022 Jun 26.
Article em En | MEDLINE | ID: mdl-35754021
ABSTRACT

BACKGROUND:

Few data exist on high flow nasal cannula (HFNC) use in patients with acute respiratory failure (ARF) admitted to general wards. RATIONALE AND

OBJECTIVES:

To retrospectively evaluate feasibility and safety of HFNC in general wards under the intensivist-supervision and after specific training.

METHODS:

Patients with ARF (dyspnea, respiratory rate-RR > 25/min, 150 < PaO2/FiO2 < 300 mmHg during oxygen therapy) admitted to nine wards of an academic hospital were included. Gas-exchange, RR, and comfort were assessed before HFNC and after 2 and 24 h of application.

RESULTS:

150 patients (81 male, age 74 [60-80] years, SOFA 4 [2-4]), 123 with de-novo ARF underwent HFNC with flow 60 L/min [50-60], FiO2 50% [36-50] and temperature 34 °C [31-37]. HFNC was applied a total of 1399 days, with a median duration of 7 [3-11] days. No major adverse events or deaths were reported. HFNC did not affect gas exchange but reduced RR (25-22/min at 2-24 h, p < 0.001), and improved Dyspnea Borg Scale (3-1, p < 0.001) and comfort (3-4, p < 0.001) after 24 h. HFNC failed in 20 patients (19.2%) 3 (2.9%) for intolerance, 14 (13.4%) escalated to NIV/CPAP in the ward, 3 (2.9%) transferred to ICU. Among these, one continued HFNC, while the other 2 were intubated and they both died. Predictors of HFNC failure were higher Charlson's Comorbidity Index (OR 1.29 [1.07-1.55]; p = 0.004), higher APACHE II Score (OR 1.59 [1.09-4.17]; p = 0.003), and cardiac failure as cause of ARF (OR 5.26 [1.36-20.46]; p = 0.02).

CONCLUSION:

In patients with mild-moderate ARF admitted to general wards, the use of HFNC after an initial training and daily supervision by intensivists was feasible and seemed safe. HFNC was effective in improving comfort, dyspnea, and respiratory rate without effects on gas exchanges. Trial registration This is a single-centre, noninterventional, retrospective analysis of clinical data.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome do Desconforto Respiratório / Insuficiência Respiratória / Ventilação não Invasiva Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome do Desconforto Respiratório / Insuficiência Respiratória / Ventilação não Invasiva Idioma: En Ano de publicação: 2022 Tipo de documento: Article